IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET

Open Research Europe, Journal Year: 2025, Volume and Issue: 4, P. 119 - 119

Published: Jan. 23, 2025

Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements both knowledge and available treatments is thus strongly felt patients, caregivers, health operators. This unmet sparked idea of orchestrating a collaborative effort via common network – IMMUPARKNET (The role IMMUnity tackling PARKinson’s through Translational NETwork). COST Action focuses challenges PD its related crosstalk with immune response. Although widely recognized, immunity onset development still unclear. main goal to fill this gap establishing an innovative, interdisciplinary research fostering exchanges expertise among specialists from different countries institutions. As we gather scientists clinicians who study fields, will establish first nucleus multidisciplinary ecosystem aims harmonize efforts approaches, clinical practice, boost ground-breaking PD. Through meetings, training schools, webinars, position papers, review manuscripts, lead fruitful know-how experts field. structure revolves around 5 working groups, total 157 active members 34 countries. Of these members, 58.5% young researchers, while 67.5% come Inclusiveness Target Countries (ITC - less research-intensive Members; https://www.cost.eu/about/members/). output facilitate improved sharing resources, straightening road novel identifying where existing ones can be repurposed, all, ultimately hopefully, finding cure PD.

Language: Английский

Activation of Pedunculopontine Tegmental Nucleus Alleviates the Pain Induced by the Lesion of Midbrain Dopaminergic Neurons

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5636 - 5636

Published: May 22, 2024

The loss of midbrain dopaminergic (DA) neurons is the fundamental pathological feature Parkinson’s disease (PD). PD causes chronic pain in two-thirds patients. Recent studies showed that activation pedunculopontine tegmental nucleus (PPTg) can effectively relieve inflammatory and neuropathic pain. PPTg located pontomesencephalic tegmentum, a target deep brain stimulation (DBS) treatment PD, involved motor control sensory integration. To test whether lesion DA induced hypersensitivity, chemogenetic could modulate pain, AAV-hM3Dq receptor was transfected expressed into 6-hydroxydopamine-lesioned mice. In this study, von Frey, open field, adhesive tape removal tests were used to assess animals’ sensitivity, locomotor activity, sensorimotor function somatosensory perception, respectively. Here, we found minor deficit voluntary movement but did not affect perception test. results led which be alleviated both by levodopa PPTg. Activating may potential therapeutic strategy phenotypes PD.

Language: Английский

Review article: the role of epigenetics as an underlying regulator of the immune responses in Parkinson’s disease

Epigenetics Reports, Journal Year: 2024, Volume and Issue: 2(1), P. 1 - 14

Published: Sept. 10, 2024

Language: Английский